SCHEMBL5339519

SCHEMBL5339519

CCOC(C=O)(CC)OCC

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28359756 0.75 ADH1B (0.34)
SCHEMBL10896628 0.75 MMP8 (0.32)
SCHEMBL11381438 0.75 ATM (0.35)
SCHEMBL8580441 0.74
SCHEMBL11296279 0.72
SCHEMBL6716656 0.71 ALDH1A1 (0.32)
SCHEMBL29242155 0.70
SCHEMBL10859017 0.69 ALDH1A1 (0.30)
SCHEMBL1536734 0.69
SCHEMBL2275108 0.69 TDP1 (0.30)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170240539-A1 Preparation and Use of Cyclic Sulfonamide Derivatives as PAR-1 Receptor Antagonists MERCK SHARP & DOHME CORP. (US) 2017-08-24 US disclosed
US-20170240539-A1 Preparation and Use of Cyclic Sulfonamide Derivatives as PAR-1 Receptor Antagonists MERCK SHARP & DOHME CORP. (US) 2017-08-24 US disclosed
US-20170240539-A1 Preparation and Use of Cyclic Sulfonamide Derivatives as PAR-1 Receptor Antagonists MERCK SHARP & DOHME CORP. (US) 2017-08-24 US disclosed
EP-3206687-A1 PREPARATION AND USE OF CYCLIC SULFONAMIDE DERIVATIVES AS PAR-1 RECEPTOR ANTAGONISTS Merck Sharp & Dohme Corp. (US) 2017-08-23 EP disclosed
WO-2016060940-A1 PREPARATION AND USE OF CYCLIC SULFONAMIDE DERIVATIVES AS PAR-1 RECEPTOR ANTAGONISTS MERCK SHARP & DOHME CORP. (US) 2016-04-21 WO disclosed
WO-2016058144-A1 PREPARATION AND USE OF CYCLIC SULFONAMIDE DERIVATIVES AS PAR-1 RECEPTOR ANTAGONISTS MERCK SHARP & DOHME CORP. (US) 2016-04-21 WO disclosed
WO-2016060940-A1 PREPARATION AND USE OF CYCLIC SULFONAMIDE DERIVATIVES AS PAR-1 RECEPTOR ANTAGONISTS MERCK SHARP & DOHME CORP. (US) 2016-04-21 WO disclosed
US-7288650-B2 Cyclic substituted fused pyrrolocarbazoles and isoindolones CEPHALON, INC. (US) 2007-10-30 US disclosed
US-7074793-B2 Cyclic substituted fused pyrrolocarbazoles and isoindolones CEPHALON, INC. (US) 2006-07-11 US disclosed
US-20060128780-A1 Cyclic substituted fused pyrrolocarbazoles and isoindolones CEPHALON, INC. (US) 2006-06-15 US disclosed
WO-2002014536-A2 ODULATING MULTIPLE LINEAGE KINASE PROTEINS CEPHALON, INC. (US) 2002-02-21 WO disclosed
EP-1165562-A1 CYCLIC SUBSTITUTED FUSED PYRROLOCARBAZOLES AND ISOINDOLONES Cephalon, Inc. (US) 2002-01-02 EP disclosed
EP-1083903-A4 BRIDGED INDENOPYRROLOCARBAZOLES CEPHALON INC (US) 2001-10-04 EP disclosed
WO-2000047583-A9 CYCLIC SUBSTITUTED FUSED PYRROLOCARBAZOLES AND ISOINDOLONES CEPHALON INC (US) 2001-09-20 WO disclosed
EP-1105728-A1 MODULATING MULTIPLE LINEAGE KINASE PROTEINS CEPHALON, INC. (US) 2001-06-13 EP disclosed
EP-1083903-A1 BRIDGED INDENOPYRROLOCARBAZOLES CEPHALON, INC. (US) 2001-03-21 EP disclosed
US-6127401-A TREATMENT OF PROSTATE DISORDERS, ANGIOGENIC DISORDERS, NEOPLASIA, RHEUMATOID ARTHRITIS, PULMONARY FIBROSIS, MYELOFIBROSIS, ABNORMAL WOUND HEALING, ATHEROSCLEROSIS, OR RESTENOSIS, ALZHEIMER'S DISEASE CEPHALON, INC. (US) 2000-10-03 US disclosed
WO-2000047583-A1 CYCLIC SUBSTITUTED FUSED PYRROLOCARBAZOLES AND ISOINDOLONES CEPHALON, INC. (US) 2000-08-17 WO disclosed
WO-2000013015-A1 MODULATING MULTIPLE LINEAGE KINASE PROTEINS CEPHALON, INC. (US) 2000-03-09 WO disclosed
WO-1999062523-A1 BRIDGED INDENOPYRROLOCARBAZOLES CEPHALON, INC. (US) 1999-12-09 WO disclosed